Abelacimab by Anthos Therapeutics for Venous (Vein) Thrombosis: Likelihood of Approval

Abelacimab is under clinical development by Anthos Therapeutics and currently in Phase I for Venous (Vein) Thrombosis.

Pharmalittle: FDA panel says popular decongestant doesn’t work; U.S. warns companies over illegally marketed eye products

Good morning, everyone, and how are you today? We are doing just fine, thank you. Given that this is already the middle of the week

September 13, 2023

Reunion Neuroscience Inc. Shareholders Approve Proposed Plan of Arrangement – Psychedelic Alpha

TORONTO, July 13, 2023 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) (“Reunion” or the “Company”), a clinical-stage biopharmaceutical company committed to developing

July 13, 2023

Alzheimer’s Drug Skepticism; Safeguarding Brain Data; Benefits of Stimulating Jobs

Physicians treating Alzheimer’s patients discussed why they’re hesitant to prescribe lecanemab (Leqembi). (Reuters) Researchers reviewed the role of neurofilament proteins in multiple sclerosis (MS), Alzheimer’s

April 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.